Kathleen P. Leneghan - 01 Apr 2022 Form 4 Insider Report for INVACARE CORP

Role: Senior VP and CFO
Signature: /s/ Kathleen P. Leneghan, by Kristofer K. Spreen, her attorney-in-fact, pursuant to Power of Attorney dated November 10, 2017, on file with the Commission
Issuer symbol: N/A
Transactions as of: 01 Apr 2022
Net transactions value: $0
Form type: 4
Filing time: 05 Apr 2022, 16:49:21 UTC
Previous filing: 15 Mar 2022
Next filing: 17 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IVC	Common Shares	Award	$0	+74,734	+45%	$0.000000	241,501	01 Apr 2022	Direct	F1
holding	IVC	Common Shares						4,976	01 Apr 2022	By Invacare Retirement Savings Plan	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	IVC	Employee Stock Option (Right to Buy)						16,000	01 Apr 2022	Common Shares	16,000		Direct	F3, F4
holding	IVC	Phantom Stock						363	01 Apr 2022	Common Shares	363		Direct	F3, F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted shares granted pursuant to the Invacare Corporation 2018 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These shares vest in 1/3 annual increments over three years commencing on May 15, 2023.
F2	Owned by the Trustee for the Invacare Retirement Savings Plan. The information given is based on a Plan Statement of December 31, 2021, the most recent information reasonably available.
F3	No transaction is being reported on this line. Reported on a previously filed Form 3, Form 4 or Form 5.
F4	The reporting person holds previously reported options to buy 16,000 Common Shares (with tandem tax withholding rights) under the Invacare Corporation 2003 Performance Plan, granted in reliance upon the exemption provided by Rule 16b-3. All options were granted between August 14, 2012 and March 18, 2013, at exercise prices between $13.37 to $14.49 per share, will expire between August 14, 2022 and March 18, 2023, and became exercisable between September 30, 2013 and March 31, 2017.
F5	Upon cessation of employment in accordance with the terms and conditions of the Invacare Corporation Deferred Compensation Plus Plan.
F6	Owned by Trustee for the Invacare Corporation Deferred Compensation Plus Plan. The information given is based on a Plan Statement of December 31, 2021, the most recent information reasonably available.